Effect of probiotics on biomarkers of cardiovascular disease: Implications for heart-healthy diets

Nutrition Reviews

Volumn 72, Issue 1, 2014, Pages 18-29

  Dirienzo, Douglas B ^a  

^a Quadrant Nutrition   (United States)

Author keywords

Cardiovascular health; Low density lipoprotein; Probiotic; Safety; Therapeutic diets

Indexed keywords

FRUCTOSE OLIGOSACCHARIDE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PROBIOTIC AGENT; SOYBEAN PROTEIN; STANOZOLOL; STEROL; SYNBIOTIC AGENT; YOGHURT;

ARTICLE; BIFIDOBACTERIUM ANIMALIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL (TOPIC); COLONY FORMING UNIT; DIETARY INTAKE; DRUG SAFETY; ENTEROCOCCUS FAECIUM; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS REUTERI; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS (TOPIC); NONHUMAN; NUTRITIONAL REQUIREMENT; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; STREPTOCOCCUS THERMOPHILUS; SYSTEMATIC REVIEW;

CARDIOVASCULAR HEALTH; LOW-DENSITY LIPOPROTEIN; PROBIOTIC; SAFETY; THERAPEUTIC DIETS;

BIFIDOBACTERIUM; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIET; HUMANS; LACTOBACILLUS ACIDOPHILUS; PROBIOTICS;

EID: 84891788298     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/nure.12084     Document Type: Article

References (93)

1. World Health Organization, World Heart Federation, World Stroke Organization. Global atlas on cardiovascular disease prevention and control. Available at: http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/index.html. Published 2011. Accessed November 14, 2013.
2. Roger VL, Go AS, Lloyd-Jones DM, etal. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-e220.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final report. Circulation. 2002;106:3143-3421.
4. Grundy SM, Cleeman JI, Merz CN, etal. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
5. Lichtenstein AH, Appel LJ, Brands M, etal. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82-96.
6. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Available at: http://www.who.int/cardiovascular_diseases/publications/Prevention_of_Cardiovascular_Disease/en/index.html. Published August 24, 2007. Accessed November 14, 2013.
7. Parvez S, Malik KA, Ah Kang S, etal. Probiotics and their fermented food products are beneficial for health. J Appl Microbiol. 2006;100:1171-1185.
8. Grundy SM. Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention. Circulation. 2008;117:569-573; discussion 573.
9. Mihaylova B, Emberson J, Blackwell L, etal. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-590.
10. Van Horn L, McCoin M, Kris-Etherton PM, etal. The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc. 2008;108:287-331.
11. Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Health and Nutritonal Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Geneva: World Health Organization; 2001.
12. de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol. 2008;111:1-66.
13. Sanz Y, Santacruz A, Gauffin P. Gut microbiota in obesity and metabolic disorders. Proc Nutr Soc. 2010;69:434-441.
14. Wallace TC, Guarner F, Madsen K, etal. Human gut microbiota and its relationship to health and disease. Nutr Rev. 2011;69:392-403.
15. Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. Guidelines for the Evaluation of Probiotics in Food. Geneva: World Health Organization; 2002.
16. Shaper AG, Jones KW, Jones M, etal. Serum lipids in three nomadic tribes of northern Kenya. Am J Clin Nutr. 1963;13:135-146.
17. Mann GV, Spoerry A. Studies of a surfactant and cholesteremia in the Maasai. Am J Clin Nutr. 1974;27:464-469.
18. Guo Z, Liu XM, Zhang QX, etal. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis. 2011;21:844-850.
19. Agerbaek M, Gerdes LU, Richelsen B. Hypocholesterolaemic effect of a new fermented milk product in healthy middle-aged men. Eur J Clin Nutr. 1995;49:346-352.
20. Anderson JW, Gilliland SE. Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J Am Coll Nutr. 1999;18:43-50.
21. Bertolami MC, Faludi AA, Batlouni M. Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia. Eur J Clin Nutr. 1999;53:97-101.
22. De Roos NM, Schouten G, Katan MB. Yoghurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels. Eur J Clin Nutr. 1999;53:277-280.
23. Agerholm-Larsen L, Raben A, Haulrik N, etal. Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. Eur J Clin Nutr. 2000;54:288-297.
24. Naruszewicz M, Johansson ML, Zapolska-Downar D, etal. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr. 2002;76:1249-1255.
25. Xiao JZ, Kondo S, Takahashi N, etal. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci. 2003;86:2452-2461.
26. Fabian E, Elmadfa I. Influence of daily consumption of probiotic and conventional yoghurt on the plasma lipid profile in young healthy women. Ann Nutr Metab. 2006;50:387-393.
27. Simons LA, Amansec SG, Conway P. Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol. Nutr Metab Cardiovasc Dis. 2006;16:531-535.
28. Ataie-Jafari A, Larijani B, Alavi Majd H, etal. Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects. Ann Nutr Metab. 2009;54:22-27.
29. Sadrzadeh-Yeganeh H, Elmadfa I, Djazayery A, etal. The effects of probiotic and conventional yoghurt on lipid profile in women. Br J Nutr. 2010;103:1778-1783.
30. Agerholm-Larsen L, Bell ML, Grunwald GK, etal. The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies. Eur J Clin Nutr. 2000;54:856-860.
31. Jones ML, Martoni CJ, Parent M, etal. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br J Nutr. 2012;107:1505-1513.
32. Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. Eur J Clin Nutr. 2012;66:1234-1241.
33. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, etal. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci. 2011;94:3288-3294.
34. Ooi LG, Ahmad R, Yuen KH, etal. Lactobacillus gasseri [corrected] CHO-220 and inulin reduced plasma total cholesterol and low-density lipoprotein cholesterol via alteration of lipid transporters. J Dairy Sci. 2010;93:5048-5058.
35. Schaafsma G, Meuling WJ, van Dokkum W, etal. Effects of a milk product, fermented by Lactobacillus acidophilus and with fructo-oligosaccharides added, on blood lipids in male volunteers. Eur J Clin Nutr. 1998;52:436-440.
36. Jones ML, Martoni CJ, Tamber S, etal. Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol. 2012;50:2216-2223.
37. Sessions VA, Lovegrove JA, Dean TX, etal. The effect of a new fermented milk product on plasma cholesterol and apolipoprotein B concentrations in middle-aged men and women. In: Sadler MJ, Saltmarsh M, eds.: Functional Foods: the Consumer, the Product and the Evidence. London: The Royal Society of Chemistry; 1998:15-20.
38. Richelsen B, Kristensen K, Pedersen SB. Long-term (6 months) effect of a new fermented milk product on the level of plasma lipoproteins - a placebo-controlled and double blind study. Eur J Clin Nutr. 1996;50:811-815.
39. Hlivak P, Odraska J, Ferencik M, etal. One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels. Bratisl Lek Listy. 2005;106:67-72.
40. Greany KA, Bonorden MJ, Hamilton-Reeves JM, etal. Probiotic capsules do not lower plasma lipids in young women and men. Eur J Clin Nutr. 2008;62:232-237.
41. Kiessling G, Schneider J, Jahreis G. Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol. Eur J Clin Nutr. 2002;56:843-849.
42. Hatakka K, Mutanen M, Holma R, etal. Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp shermanii JS administered in capsules is ineffective in lowering serum lipids. J Am Coll Nutr. 2008;27:441-447.
43. Lewis SJ, Burmeister S. A double-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids. Eur J Clin Nutr. 2005;59:776-780.
44. Lin SY, Ayres JW, Winkler W Jr, etal. Lactobacillus effects on cholesterol: in vitro and in vivo results. J Dairy Sci. 1989;72:2885-2899.
45. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologies Evaluation and Research (CBER). Guidance for industry: E9 statistical principles for clinical trials. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073137.pdf. Published September 1998. Accessed November 14, 2013
46. Wostmann BS, Wiech NL, Kung E. Catabolism and elimination of cholesterol in germfree rats. J Lipid Res. 1966;7:77-82.
47. Kellogg TF, Wostmann BS. Fecal neutral steroids and bile acids from germfree rats. J Lipid Res. 1969;10:495-503.
48. Wostmann BS. Intestinal bile acids and cholesterol absorption in the germfree rat. J Nutr. 1973;103:982-990.
49. Pereira DI, Gibson GR. Effects of consumption of probiotics and prebiotics on serum lipid levels in humans. Crit Rev Biochem Mol Biol. 2002;37:259-281.
50. Liong MT. Probiotics: a critical review of their potential role as antihypertensives, immune modulators, hypocholesterolemics, and perimenopausal treatments. Nutr Rev. 2007;65:316-328.
51. Tosetto A, Prati P, Baracchini C, etal. Association of plasma fibrinogen, C-reactive protein and G-455>A polymorphism with early atherosclerosis in the VITA Project cohort. Thromb Haemost. 2011;105:329-335.
52. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin. 2003;21:315-325.
53. Pearson TA, Mensah GA, Alexander RW, etal. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
54. Ridker PM, Danielson E, Fonseca FA, etal. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
55. Hakansson A, Molin G. Gut microbiota and inflammation. Nutrients. 2011;3:637-682.
56. Fiorucci S, Cipriani S, Baldelli F, etal. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res. 2010;49:171-185.
57. Pols TW, Noriega LG, Nomura M, etal. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol. 2011;54:1263-1272.
58. Kawamata Y, Fujii R, Hosoya M, etal. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278:9435-9440.
59. Pols TW, Nomura M, Harach T, etal. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011;14:747-757.
60. Fiorucci S, Cipriani S, Mencarelli A, etal. Counter-regulatory role of bile acid activated receptors in immunity and inflammation. Curr Mol Med. 2010;10:579-595.
61. Ebringer L, Ferencik M, Krajcovic J. Beneficial health effects of milk and fermented dairy products-review. Folia Microbiol (Praha). 2008;53:378-394.
62. Jenkins DJ, Kendall CW, Marchie A, etal. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290:502-510.
63. Jenkins DJ, Kendall CW, Faulkner DA, etal. Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. Am J Clin Nutr. 2006;83:582-591.
64. US Food and Drug Administration, Department of Health and Human Services. Code of Federal Regulations. Health claims: plant sterol/stanol esters and risk of coronary heart disease (CHD). 21C.F.R.101.83. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=101.83. Revised April 1, 2013. Accessed November 15, 2013.
65. EFSA Panel on Dietetic Products Nutrition and Allergies (NDA). Scientific opinion on the substantiation of a health claim related to 3g/day plant sterols/stanols and lowering blood LDL-cholesterol and reduced risk of (coronary) heart disease pursuant to Article 19 of Regulation (EC) No 1924/2006. EFSA J. 2012;10:2693.
66. Katan MB, Grundy SM, Jones P, etal. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003;78:965-978.
67. Gupta AK, Savopoulos CG, Ahuja J, etal. Role of phytosterols in lipid-lowering: current perspectives. QJM. 2011;104:301-308.
68. Abumweis SS, Barake R, Jones PJ. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res. 2008;52. doi:10.3402/fnr.v52i0.1811.
69. Anderson JW, Allgood LD, Lawrence A, etal. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr. 2000;71:472-479.
70. Gunness P, Gidley MJ. Mechanisms underlying the cholesterol-lowering properties of soluble dietary fibre polysaccharides. Food Funct. 2010;1:149-155.
71. US Food and Drug Administration, Department of Health and Human Services. Code of Federal Regulations. Health claims: soluble fibers from certain foods and risk of coronary heart disease (CHD). 21C.F.R.101.81. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=101.81. Revised April 1, 2013. Accessed November 15, 2013.
72. EFSA Panel on Dietetic Products Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of a health claim related to oat beta-glucan and lowering blood cholesterol and reduced risk of (coronary) health disease pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J. 2010;8:1885.
73. EFSA Panel on Dietetic Products Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of a health claim related to barley beta-glucans and lowering of blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J. 2011;9:2470.
74. Tiwari U, Cummins E. Meta-analysis of the effect of beta-glucan intake on blood cholesterol and glucose levels. Nutrition. 2011;27:1008-1016.
75. US Food and Drug Administration, Department of Health and Human Services. Code of Federal Regulations. Health claims: Soy protein and risk of coronary heart disease (CHD). 21C.F.R.101.82. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=101.82. Revised April 1, 2013. Accessed November 15, 2013.
76. Anderson JW, Bush HM. Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies. J Am Coll Nutr. 2011;30:79-91.
77. Nijjar PS, Burke FM, Bloesch A, etal. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol. 2010;4:248-258.
78. Jones PH, Davidson MH, Stein EA, etal. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-160.
79. Jones P, Kafonek S, Laurora I, etal. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-587.
80. Micropharma Ltd. Lactobacillus reuteri NCIMB 30242. GRAS Notice. 2012; Available at: http://www.accessdata.fda.gov/scripts/fcn/gras_notices/GRN000440.pdf. Accessed November 15, 2013.
81. Wolf B, Garleb K, Ataya D, etal. Safety and tolerance of Lactobacillus reuteri in healthy adult male subjects. Microb Ecol Health Dis. 1995;8:41-50.
82. US Food and Drug Administration, CFSAN/Office of Food Additive Safety. Agency response letter GRAS notice no. GRN 000254. 2008; Available at: http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm154990.htm. Accessed November 15, 2013.
83. Department of Health and Ageing, Therapeutic Goods Administration. Substances that may be used in listed medicines in Australia. Available at: http://www.tga.gov.au/pdf/cm-listed-substances.pdf. Published December 2007. Accessed November 14, 2013.
84. EFSA Panel on Biological Hazards (BIOHAZ). Scientific Opinion on the maintenance of the list of QPS microorganisms intentionally added to food or feed (2009 update). EFSA J. 2009;7:1431.
85. Weizman Z, Alsheikh A. Safety and tolerance of a probiotic formula in early infancy comparing two probiotic agents: a pilot study. J Am Coll Nutr. 2006;25:415-419.
86. Connolly E, Abrahamsson T, Bjorksten B. Safety of D(-)-lactic acid producing bacteria in the human infant. J Pediatr Gastroenterol Nutr. 2005;41:489-492.
87. Branton W, Jones M, Tomaro-Duchesneau C, etal. In vitro characterization and safety of the probiotic strain Lactobacillus reuteri cardioviva NCIMB 30242. Int J Probiotics Prebiotics. 2010;6:1-12.
88. Jones ML, Martoni CJ, Di Pietro E, etal. Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial. Regul Toxicol Pharmacol. 2012;63:313-320.
89. US Food and Drug Administration. GRAS notice inventory. GRN no. 440. 2012; Available at: http://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?rpt=grasListing&displayAll=false&page=1. Accessed November 14, 2013.
90. US Food and Drug Administration. CFSAN/Office of Food Additive Safety. Agency response letter GRAS notice no. GRN 000049. Available at: http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm153759.htm. Accessed November 15, 2013.
91. Ogier JC, Serror P. Safety assessment of dairy microorganisms: the Enterococcus genus. Int J Food Microbiol. 2008;126:291-301.
92. Franz CM, Huch M, Abriouel H, etal. Enterococci as probiotics and their implications in food safety. Int J Food Microbiol. 2011;151:125-140.
93. US Food and Drug Administration. Draft guidance for industry: dietary supplements: new dietary ingredient notifications and related issues. Available at: http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/dietarysupplements/ucm257563.htm. Published July 2011. Accessed November 15, 2013.